Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy-a propensity-adjusted analysis

American Heart Journal

Volumn 151, Issue 5, 2006, Pages 1031.e1-1031.e6

  Gurm, Hitinder S ^a   Breitbart, Yuri ^b   Vivekanathan, Deepak ^a   Yen, Michael H ^a   Fathi, Robert ^a   Ziada, Khaled M ^a   Whitlow, Patrick L ^a   Ellis, Stephen G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOTONIC AGENT; FIBRINOGEN RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; ROTATIONAL ATHERECTOMY; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; ATHERECTOMY; CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; HEART MUSCLE; HOSPITALIZATION; MIDDLE AGED; NECROSIS; PATHOLOGY; PREMEDICATION; STATISTICAL MODEL;

AGED; ATHERECTOMY, CORONARY; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIUM; NECROSIS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; SEVERITY OF ILLNESS INDEX;

EID: 33646078311     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.02.026     Document Type: Article

References (29)

1. Gurm H.S., and Ellis S.G. Periprocedural myonecrosis: from a laboratory anomaly to a sentinel of risk. Ital Heart J 4 (2003) 1-3
2. Ellis S.G., Chew D., Chan A., et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 106 (2002) 1205-1210
3. Abdelmeguid A.E., Ellis S.G., Sapp S.K., et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J 131 (1996) 1097-1105
4. Abdelmeguid A.E., and Topol E.J. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 94 (1996) 3369-3375
5. Abdelmeguid A.E., Topol E.J., Whitlow P.L., et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 94 (1996) 1528-1536
6. Adams III J.E., Abendschein D.R., and Jaffe A.S. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s?. Circulation 88 (1993) 750-763
7. Califf R.M., Abdelmeguid A.E., Kuntz R.E., et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 31 (1998) 241-251
8. Pasceri V., Patti G., Nusca A., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
9. Hoffmann R., Mintz G.S., Kent K.M., et al. Comparative early and nine-month results of rotational atherectomy, stents, and the combination of both for calcified lesions in large coronary arteries. Am J Cardiol 81 (1998) 552-557
10. Reisman M., Harms V., Whitlow P., et al. Comparison of early and recent results with rotational atherectomy. J Am Coll Cardiol 29 (1997) 353-357
11. Ellis S.G., Guetta V., Miller D., et al. Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: an analysis of results from 10,907 lesions and proposal for new classification scheme. Circulation 100 (1999) 1971-1976
12. Brin S., Motwani R., and Silverstein C. Beyond market baskets: generalizing association rules to correlations. ACM SIGMOD Conference on Management of Data (1997) 265-276
13. Ricciardi M.J., Wu E., Davidson C.J., et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 103 (2001) 2780-2783
14. Kini A., Kini S., Marmur J.D., et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 48 (1999) 123-129
15. Hansen D.D., Auth D.C., Vracko R., et al. Rotational atherectomy in atherosclerotic rabbit iliac arteries. Am Heart J 115 (1988) 160-165
16. Hansen D.D., Auth D.C., Hall M., et al. Rotational endarterectomy in normal canine coronary arteries: preliminary report. J Am Coll Cardiol 11 (1988) 1073-1077
17. Williams M.J., Dow C.J., Newell J.B., et al. Prevalence and timing of regional myocardial dysfunction after rotational coronary atherectomy. J Am Coll Cardiol 28 (1996) 861-869
18. Farb A., Roberts D.K., Pichard A.D., et al. Coronary artery morphologic features after coronary rotational atherectomy: insights into mechanisms of lumen enlargement and embolization. Am Heart J 129 (1995) 1058-1067
19. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106 (2002) 2180-2183
20. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
21. Jones S.P., Gibson M.F., Rimmer III D.M., et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
22. Lefer A.M., Campbell B., Shin Y.K., et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
23. Quillen J.E., Sellke F.W., Brooks L.A., et al. Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation 82 (1990) 586-594
24. Jones S.P., Teshima Y., Akao M., et al. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93 (2003) 697-699
25. Akao M., O'Rourke B., Kusuoka H., et al. Differential actions of cardioprotective agents on the mitochondrial death pathway. Circ Res 92 (2003) 195-202
26. Oldenburg O., Cohen M.V., Yellon D.M., et al. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res 55 (2002) 429-437
27. EPISTENT. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 352 (1998) 87-92
28. EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 330 (1994) 956-961
29. Stone G.W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108 (2003) 548-553